Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Loaded Mir-29-3p Targets AhR to Improve Juvenile Idiopathic Arthritis Via Inhibiting the Expression of IL-22 in CD4 T Cell

Overview

Journal Stem Cell Rev Rep

Publisher Springer

Specialty Cell Biology

Date 2024 Dec 2

PMID 39621151

Authors

Xinyi Wei

Kunpeng Sui

Yuanyuan Peng

Sha Li

Yu Fang

Zhi Chen

Xiao Du

Xue Xie

Haiming Tang

QiuYue Wen

Jingwei Li

Meilin He

Qin Cheng

Wei Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Juvenile idiopathic arthritis (JIA) is one of the most common chronic inflammatory rheumatic diseases in children. Human umbilical cord mesenchymal stem cells (HUCMSCs)-derived exosomes (HUCMSCs-Exos) are involved in autoimmune diseases. This study investigates the mechanism of HUCMSC-Exos in improving JIA by targeting AhR through delivery of miR-29-3p to inhibit IL-22 expression in CD4 T cells.

Methods: Collagen induced arthritis (CIA) mouse model was established, and mice were treated with HUCMSCs-Exos and miR-29-3p antagomir, respectively. CD4 T cells from JIA patients were used for cell experiments. The mechanism was elucidated by histopathological staining, transmission electron microscopy (TEM), immunohistochemistry, CCK-8 assay, flow cytometry, Western blotting, real-time PCR, and enzyme-linked immunosorbent assay (ELISA), laser confocal microscopy, and luciferase assay.

Result: JIA-CD4 T cells showed higher expression of IL-22 and lower the levels of miR-29-3p, while HUCMSCs-Exos significantly inhibited the expression of IL-22 and increased the levels of miR-29a-3p, miR-29b-3p, and miR-29c-3p in CD4 T cells from JIA patients. The expression of miR-29a-3p, miR-29b-3p, miR-29c-3p, AhR, and IL-22 in CD4 T cells was significantly reversed when co-cultured with HUCMSCs transfected with miR-29-3p mimic or miR-29-3p inhibitor. In vivo experiment, HUCMSCs-Exos ameliorated CIA mice by delivering miR-29-3p to inhibit AhR, IL-22, IL-22R1, MMP3, and MMP13 expression. Furthermore, HUCMSCs-Exos also deliver miR-29-3p targeting AhR expression to inhibit IL-22 in JIA-CD4 + T cells through alleviating arthritic synovial fibroblast activation.

Conclusion: HUCMSCs-Exos loaded miR-29-3p targets AhR to improve JIA via inhibiting the expression of IL-22 in CD4 T cell, which provides a scientific basis for the treatment of JIA.

References

Martini A, Lovell D, Albani S, Brunner H, Hyrich K, Thompson S . Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022; 8(1):5. DOI: 10.1038/s41572-021-00332-8. View

Sen E, Ramanan A . Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2019; 211:108322. DOI: 10.1016/j.clim.2019.108322. View

Zaripova L, Midgley A, Christmas S, Beresford M, Baildam E, Oldershaw R . Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021; 19(1):135. PMC: 8383464. DOI: 10.1186/s12969-021-00629-8. View

Nigrovic P, Martinez-Bonet M, Thompson S . Implications of juvenile idiopathic arthritis genetic risk variants for disease pathogenesis and classification. Curr Opin Rheumatol. 2019; 31(5):401-410. PMC: 6800096. DOI: 10.1097/BOR.0000000000000637. View

Paroli M, Spadea L, Caccavale R, Spadea L, Paroli M, Nante N . The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment. Medicina (Kaunas). 2022; 58(11). PMC: 9696590. DOI: 10.3390/medicina58111552. View

Rebane K, Aalto K, Haanpaa M, Puolakka K, Virta L, Kautiainen H . Initiating disease-modifying anti-rheumatic drugs rapidly reduces purchases of analgesic drugs in juvenile idiopathic arthritis. Scand J Rheumatol. 2020; 50(1):28-33. DOI: 10.1080/03009742.2020.1762923. View

Renton W, Jung J, Palestine A . Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Rev. 2022; 10:CD013818. PMC: 9562090. DOI: 10.1002/14651858.CD013818.pub2. View

Lee J, Schneider R . Systemic Juvenile Idiopathic Arthritis. Pediatr Clin North Am. 2018; 65(4):691-709. DOI: 10.1016/j.pcl.2018.04.005. View

Grevich S, Shenoi S . Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017; 8:125-135. PMC: 5687245. DOI: 10.2147/AHMT.S109495. View

10.

Imbrechts M, Avau A, Vandenhaute J, Malengier-Devlies B, Put K, Mitera T . Insufficient IL-10 Production as a Mechanism Underlying the Pathogenesis of Systemic Juvenile Idiopathic Arthritis. J Immunol. 2018; 201(9):2654-2663. DOI: 10.4049/jimmunol.1800468. View

11.

Leipe J, Schramm M, Grunke M, Baeuerle M, Dechant C, Nigg A . Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis. 2011; 70(8):1453-7. DOI: 10.1136/ard.2011.152074. View

12.

Ren J, Feng Z, Lv Z, Chen X, Li J . Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-α. J Rheumatol. 2011; 38(10):2112-8. DOI: 10.3899/jrheum.101377. View

13.

Chavez-Valencia R, Chiaroni-Clarke R, Martino D, Munro J, Allen R, Akikusa J . The DNA methylation landscape of CD4 T cells in oligoarticular juvenile idiopathic arthritis. J Autoimmun. 2017; 86:29-38. DOI: 10.1016/j.jaut.2017.09.010. View

14.

Hou W, Duan L, Huang C, Li X, Xu X, Qin P . Cross-Tissue Characterization of Heterogeneities of Mesenchymal Stem Cells and Their Differentiation Potentials. Front Cell Dev Biol. 2022; 9:781021. PMC: 8719164. DOI: 10.3389/fcell.2021.781021. View

15.

Ciuffreda M, Malpasso G, Musaro P, Turco V, Gnecchi M . Protocols for in vitro Differentiation of Human Mesenchymal Stem Cells into Osteogenic, Chondrogenic and Adipogenic Lineages. Methods Mol Biol. 2016; 1416:149-58. DOI: 10.1007/978-1-4939-3584-0_8. View

16.

Squillaro T, Peluso G, Galderisi U . Clinical Trials With Mesenchymal Stem Cells: An Update. Cell Transplant. 2015; 25(5):829-48. DOI: 10.3727/096368915X689622. View

17.

Hoang D, Pham P, Bach T, Ngo A, Nguyen Q, Phan T . Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022; 7(1):272. PMC: 9357075. DOI: 10.1038/s41392-022-01134-4. View

18.

Miceli V, Bulati M, Iannolo G, Zito G, Gallo A, Conaldi P . Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine. Int J Mol Sci. 2021; 22(2). PMC: 7828743. DOI: 10.3390/ijms22020763. View

19.

Hwang J, Rim Y, Nam Y, Ju J . Recent Developments in Clinical Applications of Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis and Osteoarthritis. Front Immunol. 2021; 12:631291. PMC: 7982594. DOI: 10.3389/fimmu.2021.631291. View

20.

Cosenza S, Toupet K, Maumus M, Luz-Crawford P, Blanc-Brude O, Jorgensen C . Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics. 2018; 8(5):1399-1410. PMC: 5835945. DOI: 10.7150/thno.21072. View